St. Louis, MO-based Sigma-Aldrich's SAFC custom manufacturing business is making investments that will lead to commercial-scale antibody drug conjugates manufacturing at a facility in St. Louis.
There has been a big rush towards biologics manufacturing as drugmakers prepare for the new drugs that are becoming a larger piece of their portfolios. Swiss drugmaker Roche say it has 39 biologics in development.
Swiss drugmaker Roche has seen explosive growth for drugs like its new breast cancer drug Kadcyla and says it needs a lot more capacity for it and the long list of other biologics in hand or under development. To get that capacity, it will invest nearly $900 million to build a new facility in Switzerland and expand plants in the U.S. and Germany, adding nearly 500 jobs in the process.
Roche previewed part of its future this summer, debuting one of two new molecular diagnostics platforms at industry conferences in Italy and The Netherlands. Now, the Swiss giant is in the early stages of prepping for a launch next year in Europe and Japan of both systems – cobas 6800 and cobas 8800.
The online chatter in Bloomberg and Reuters about potential Roche deals has been flying fast and furious recently, but there's been a streak of unfounded rumors that appear to be more smoke than fire.
News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in deals that could be worth $15 billion to $20 billion. And no, Roche and Novartis aren't likely to embark on any big joint projects, much less consider a merger.
In drug development, everything's a gamble, if you're doing something new and shooting at a big target. But there has to be a reasonable assumption that if safety issues aren't being glossed over and the efficacy data hold up, these top drugs can change standards of care and grab market share. So here's my pick of the likely big winners >>
The interest in vaccine deals stems from a belief that tweaking the immune system can have a major impact on cancer care.
When John Reed headed up Sanford-Burnham Medical Research Institute, the marathon runner was well known for early starts and fast finishes. And now, as the new head of Roche's Basel-based Pharma Research and Early Development group--better known as pRED--he's in for the run of his life. Read the full feature >>
Perjeta is now the first cancer drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive breast cancer, Perjeta can now reach a huge new group of patients at early stages of the disease.